Wiener klinische Wochenschrift

, Volume 122, Issue 17–18, pp 532–537 | Cite as

Pharmacologic undertreatment of osteoporosis in Austrian nursing homes and senior's residences

  • Peter Pietschmann
  • Ursula Azizi-Semrad
  • Katharina Pils
  • Astrid Fahrleitner-Pammer
  • Heinrich Resch
  • Harald Dobnig
original article

Summary

Osteoporosis is a classical age-related disease. Although significant progress in treatment has been achieved and antifracture efficacy proven over the past years undertreatment is still a general problem. There are only few published data available regarding osteoporosis and its treatment encountered in Austrian nursing homes and seniors' residences where fractures are especially frequent. We therefore conducted a survey in 89 participating institutions in order to assess frequency of documented osteoporosis as well as prevalence status of anti-osteoporotic drug usage in this special population. Data were acquired using a questionnaire and analyzed in a descriptive manner. Mean age of the residents was 82 years and the majority was female (76%). Half of the subjects took 5–8 different drugs per day and 23% received more than 8. Almost onefourth (21.2%) of the residents had a diagnosis of osteoporosis. A history of hip fracture or other fractures was documented in 10.4% and 13.2%, respectively. Only 8.2% of the residents were treated with calcium, 6.2% with vitamin D and 9.3% received a combination of vitamin D and calcium. Specific osteoporosis treatment was prescribed to 7.2% only. In conclusion, this study reflects a high degree of continuing unawareness toward a diagnosis of osteoporosis in Austrian nursing homes and seniors' residences. The data of this survey further indicate that undertreatment is still very common in this population at very high risk of fractures.

Keywords

Nursing home Osteoporosis Multi-medication Falls 

Pharmakologische Unterversorgung der Osteoporose bei österreichischen Pflege- und Pensionistenheimbewohnern

Zusammenfassung

Die Osteoporose ist eine klassische, altersabhängige Erkrankung. Obwohl in den vergangenen Jahren wesentliche Erfolge bei der Behandlung der Osteoporose erzielt und die Antifraktur-Wirkung einiger Medikamente bestätigt werden konnte, ist die Unterversorgung der Osteoporose nach wie vor ein wesentliches Problem. Bis dato existieren nur wenige Studien, die sich spezifi sch mit der Osteoporose und ihrer Behandlung in österreichischen Pflege- und Pensionistenheimen auseinandersetzen. Um die Häufigkeit der diagnostizierten Osteoporosefälle sowie die Verschreibung von Medikamenten gegen die Osteoporose zu untersuchen, haben wir eine Erhebung bei 89 teilnehmenden Institutionen durchgeführt. Die Daten wurden durch einen Fragebogen erhoben und mittels deskriptiven statistischen Verfahren ausgewertet. Das Durchschnittsalter der Heimbewohner betrug 82 Jahre, wobei der Großteil weiblich war (76 %). Die Hälfte der Bewohner nahm 5–8 verschiedene Medikamente pro Tag ein; 23 % erhielten sogar mehr als 8 Medikamente. Bei fast einem Viertel (21,2 %) der Heimbewohner lag die Diagnose einer Osteoporose vor. Die Anamnese einer Hüftfraktur lag bei 10,4 %, die einer anderen Fraktur bei 13,2 % vor. Lediglich 8,2 % der Bewohner wurden mit Kalzium, 6,2 % mit Vitamin D und 9,3 % mit einer Kombination aus Vitamin D und Kalzium behandelt. Nur bei 7,2 % war eine spezifi sche Osteoporosebehandlung verordnet worden. Zusammenfassend zeigt unsere Studie bestehende Mängel bei der Diagnose der Osteoporose in den österreichischen Pflege- und Pensionistenheimen auf. Die Daten unserer Erhebung weisen sehr deutlich darauf hin, dass die Osteoporose nach wie vor gerade in dem Bevölkerungsanteil, bei dem das größte Frakturrisiko besteht, nicht ausreichend versorgt wird.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anonymous (2001) Osteoporosis prevention, diagnosis and therapy. JAMA 285: 785–95CrossRefGoogle Scholar
  2. Dimai HP, Pietschmann P, Resch H, Preisinger E, Fahrleitner-Pammer A, Dobnig H, et al (2009) Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women – update 2009. Wien Med Wochenschr 122[Suppl]: 1–34CrossRefGoogle Scholar
  3. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19(4): 399–428CrossRefPubMedGoogle Scholar
  4. Solomon DH, Morris C, Cheng H, Cabral D, Katz JN, Finkelstein JS, et al (2005) Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc 80(2): 194–202CrossRefPubMedGoogle Scholar
  5. Colón-Emeric C, Lyles KW, Levine DA, House P, Schenck A, Gorospe J, et al (2007) Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture. Osteoporos Int 18(4): 553–9CrossRefPubMedGoogle Scholar
  6. Wright RM (2007) Use of osteoporosis medications in older nursing facility residents. J Am Med Dir Assoc 8(7): 453–7CrossRefPubMedGoogle Scholar
  7. Vik SA, Maxwell CJ, Hanley DA (2005) Treatment of osteoporosis in an older home care population. BMC Musculoskelet Disord 6: 7CrossRefPubMedGoogle Scholar
  8. Panneman MJ, Lips P, Sen SS, Herings RM (2004) Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 15(2): 120–4CrossRefPubMedGoogle Scholar
  9. Sloane PD, Gruber-Baldini AL, Zimmerman S, Roth M, Watson L, Boustani M, et al (2004) Medication undertreatment in assisted living settings. Arch Intern Med 164(18): 2031–7CrossRefPubMedGoogle Scholar
  10. Rojas-Fernandez CH, Lapane KL, MacKnight C, Howard KA (2002) Undertreatment of osteoporosis in residents of nursing homes: population-based study with use of the Systematic Assessment of Geriatric Drug Use via Epidemiology (SAGE) database. Endocr Pract 8(5): 335–42PubMedGoogle Scholar
  11. Haaland DA, Cohen DR, Kennedy CC, Khalidi NA, Adachi JD, Papaioannou A (2009) Closing the osteoporosis care gap – increased osteoporosis awareness among geriatrics and rehabilitation teams. BMC Geriatr 9(1): 28CrossRefPubMedGoogle Scholar
  12. Gardner MJ, Flik KR, Mooar P, Lane JM (2002) Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Joint Surg Am 84-A(8): 1342–8PubMedGoogle Scholar
  13. Jaglal SB, Weller I, Mamdani M, Hawker G, Kreder H, Jaakkimainen L, et al (2005) Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res 20(6): 898–905CrossRefPubMedGoogle Scholar
  14. Kannus P, Niemi S, Parkkari J, Palvanen M, Vuori I, Järvinen M (2006) Nationwide decline in incidence of hip fracture. J Bone Miner Res 21(12): 1836–8CrossRefPubMedGoogle Scholar
  15. Dorner T, Weichselbaum E, Lawrence K, Viktoria Stein K, Rieder A (2009) Austrian Osteoporosis Report: epidemiology, lifestyle factors, public health strategies. Wien Med Wochenschr 159(9–10): 221–9CrossRefPubMedGoogle Scholar
  16. Dobnig H, Piswanger-Sölkner JC, Roth M, Obermayer Pietsch B, Tiran A, Strele A, Maier E, Maritschnegg P, Sieberer C, Fahrleitner-Pammer A (2006) Type 2 diabetes mellitus in nursing home patients: eff ects on bone turno-ver, bone mass, and fracture risk. J Clin Endocrin Metab 91(9): 3355–63CrossRefGoogle Scholar
  17. Dobnig H, Piswanger-Sölkner C, Obermayer-Pietsch B, Tiran A, Strele A, Maier E, Maritschnegg P, Riedmüller G, Brueck C, Fahrleitner-Pammer A (2007) Hip and nonvertebral fracture prediction in nursing home patients: role of bone ultrasound and bone marker measurements. J Clin Endocrin Metab 92(5): 1678–86CrossRefGoogle Scholar
  18. Frankfort SV, Tulner LR, van Campen JP, Koks CH, Beijnen JH (2006) Evaluation of pharmacotherapy in geriatric patients after performing complete geriatric assessment at a diagnostic day clinic. Clin Drug Investig 26(3): 169–74CrossRefPubMedGoogle Scholar
  19. Rapp K, Becker C, Lamb SE, Icks A, Klenk J (2008) Hip fractures in institutionalized elderly people: incidence rates and excess mortality. J Bone Miner Res 23(11): 1825–31CrossRefPubMedGoogle Scholar
  20. Zimmerman SI, Girman CJ, Buie VC, Chandler J, Hawkes W, Martin A, et al (1999) Th e prevalence of osteoporosis in nursing home residents. Osteoporos Int 9(2): 151–7CrossRefPubMedGoogle Scholar
  21. Sallin U, Mellström D, Eggertsen R (2005) Osteoporosis in a nursing home, determined by the DEXA technique. Med Sci Monit 11(2): CR67–70PubMedGoogle Scholar
  22. Kenny AM, Smith J, Noteroglu E, Waynik IY, Ellis C, Kleppinger A, et al (2009) Osteoporosis risk in frail older adults in assisted living. J Am Geriatr Soc 57(1): 76–81CrossRefPubMedGoogle Scholar
  23. Bischoff -Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, et al (2009) Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 169(6): 551–61CrossRefPubMedGoogle Scholar
  24. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, et al (1992) Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327(23): 1637–4CrossRefPubMedGoogle Scholar
  25. Boonen S, Laan RF, Barton IP, Watts NB (2005) Eff ect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 16(10): 1291–8CrossRefPubMedGoogle Scholar
  26. Cole ZA, Dennison EM, Cooper C (2008) Osteoporosis epidemiology update. Curr Rheumatol Rep 10(2): 92–6CrossRefPubMedGoogle Scholar
  27. Dennison E, Cole Z, Cooper C (2005) Diagnosis and epidemiology of osteoporosis. Curr Opin Rheumatol 17(4): 456–61CrossRefPubMedGoogle Scholar
  28. Lyles KW, Schenck AP, Colón-Emeric CS (2008) Hip and other osteoporotic fractures increase the risk of subsequent fractures in nursing home residents. Osteoporos Int 19(8): 1225–33CrossRefPubMedGoogle Scholar
  29. Sugarman JR, Connell FA, Hansen A, Helgerson SD, Jessup MC, Lee H (2002) Hip fracture incidence in nursing home residents and community-dwelling older people, Washington State, 1993–1995. J Am Geriatr Soc 50(10): 1638–43CrossRefPubMedGoogle Scholar
  30. Chandler JM, Zimmerman SI, Girman CJ, Martin AR, Hawkes W, Hebel JR, et al (2000) Low bone mineral density and risk of fracture in white female nursing home residents. JAMA 284(8): 972–7CrossRefPubMedGoogle Scholar
  31. Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM (2006) Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 21(7): 1113–20CrossRefPubMedGoogle Scholar
  32. Lyles KW, Colón-Emeric CS, Magazinger JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18): 1799–809CrossRefPubMedGoogle Scholar
  33. Cramer JA, Gold DT, Silverman SL, Lewiecky EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18: 1023–31CrossRefPubMedGoogle Scholar
  34. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54(6): 1838–46CrossRefPubMedGoogle Scholar
  35. Sebba AI, Emkey RD, Kohles JD, Sambrook PN (2009) Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone 44(3): 423–7CrossRefPubMedGoogle Scholar
  36. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18): 1809–22CrossRefPubMedGoogle Scholar
  37. Premaor MO, Pilbrow L, Tonkin C, Adams M, Parker RA, Compston J (2010) Low rates of treatment in postmenopausal women with a history of low trauma fractures: results of audit in a Fracture Liaison Service. QJM 103(1): 33–40CrossRefPubMedGoogle Scholar
  38. Jensen J, Lundin-Olsson L, Nyberg L, Gustafson Y (2002) Fall and injury prevention in older people living in residential care facilities. A cluster randomized trial. Ann Intern Med 136(10): 733–41PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Peter Pietschmann
    • 1
  • Ursula Azizi-Semrad
    • 1
  • Katharina Pils
    • 2
  • Astrid Fahrleitner-Pammer
    • 3
  • Heinrich Resch
    • 4
  • Harald Dobnig
    • 3
  1. 1.Department of Pathophysiology and Allergy Research, Center of PathophysiologyInfectiology and Immunology, Medical University of ViennaViennaAustria
  2. 2.Institute for Physical Medicine and RehabilitationSMZ-SophienspitalViennaAustria
  3. 3.Division of Endocrinology and Metabolism, Department of Internal MedicineMedical University of GrazGrazAustria
  4. 4.Medical Department IISt. Vincent HospitalViennaAustria

Personalised recommendations